HomeMedical SpecialtiesMEDICAL SPECIALTIESResearch aims to identify resistance to breast cancer treatment

Research aims to identify resistance to breast cancer treatment

Published on

A simple test could improve the treatment odds of patients diagnosed with breast cancer, thanks to new research at The University of Winnipeg.

The drug Tamoxifen, used to treat the majority of breast cancer cases, is ineffective in approximately half of all patients who receive it. Dean Reddick, a graduate student in the Master of Science in Bioscience, Technology and Public Policy, is researching a way to identify these patients before treatment starts — saving valuable time in the process.

“You have a patient who has cancer, they’re taking the drug, and both the patient and the physician are thinking the treatment is working. Meanwhile, it’s not working at all and the cancer’s growing very rapidly, and nobody knows that,” said Reddick, who won UWinnipeg’s Three Minute Thesis competition in April.

The research impacts the treatment of estrogen receptor positive (ER+) breast cancer, which accounts for approximately 70 per cent of all breast cancer cases, and is characterized by estrogen binding to an abnormal number of receptors. Doctors typically prescribe Tamoxifen at the start of any ER+ treatment, thanks to its success rate in patients who are responsive to it.

Cancer-patient wait times could be reduced by 44%

“Tamoxifen is a fantastic drug that delivers targeted therapy to ER+ breast cancer, however not all ER+ breast cancer patients respond to it,” said UWinnipeg biology professor Dr. Anuraag Shrivastav, whose lab has been studying the topic for several years.

Key to solving the issue is a protein within cancer cells known as N-Myristoyltransferase (NMT), which the lab has already discovered activates with increased estrogen receptor activity. Since last September, Reddick has produced 14 different variants of breast cancer cells, each with different localizations of the protein. The plan is now to treat each one and monitor their responses.

“We want to see if these different places where [NMT] is found can actually be acting as a predictive biomarker,” said Reddick. “For instance, if you find all this protein inside the nucleus, are those cells going to be resistant to Tamoxifen or responsive to it?”

Although the lab still has further testing to do, Reddick believes the protein is an indicator of responsive cells.

“We think that [NMT] may be influencing genes that are related to cancer development and actually stopping them from being read and turned into protein. If that’s the case, then that’s going to be good for the patient, because that’s going to slow down cancer growth, period. It could also be slowing down genes that are related to the development of the resistance.”

Once the indicators are identified, Reddick says within three to four years a biopsy could be used to determine a patient’s resistance level and prescribe appropriate treatment.

“Chemotherapy is never ideal, but it is better than a drug that has no effect.”

Latest articles

Popular CT Scans Could Account for 5% of All Cancer Cases A Year

Radiation from imaging could lead to lung, breast and other future cancers, with 10-fold...

Breaking Barriers with Mobile Care

In Canada, marginalized populations face many barriers to accessing the health care they need,...

Advancing women’s health research and care

Historically, women have faced barriers in the diagnosis, treatment and care of many health...

It is time the feds make the long-awaited diabetes device fund a reality

It has been almost a year since the federal government announced that it would...

More like this

High blood pressure? Eat more bananas

New mathematical model demonstrates ratio of potassium to sodium intake key to regulating blood...

UHN addressing care gap in women’s heart health

Elana Trainoff didn’t think it was possible to have a heart attack at age...

Transgender and gender diverse people less likely to receive follow-up after a mental health hospitalization

Transgender and gender diverse individuals who were hospitalized for psychiatric care were less likely...

Smart radar device warns of serious heart issues

Waterloo researchers develop “super-sensitive” radar technology that can unobtrusively monitor heartbeats. Dr. George Shaker has...

Canada’s emergency departments are overwhelmed. Can patient redirection help?

Across Canada, emergency departments are facing an unprecedented surge in patient volumes, stretching resources...

Canada’s first pre-hospital blood transfusion trial could be a ‘lifeline’ for trauma patients

Dr. Brodie Nolan’s latest study takes scientific research into the air to bring hospital-quality...